Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Nutex Health Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-6.6% vs price
Base Case (Median)
24.0% vs price
Bull Case (75th pct.)
177.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $221.69 | 14.3% | High (40%) |
| PE Comparable | $662.42 | 241.6% | Medium (25%) |
| Growth Trajectory DCF | $631.31 | 225.6% | Medium (20%) |
| Graham Number | $167.48 | -13.6% | Low (10%) |
| EV/EBITDA | $259.02 | 33.6% | Medium (20%) |
| Earnings Power Value | $105.06 | -45.8% | Medium (50%) |
Based on 6 out of 8 methods, NUTX appears fairly valued at the current price of $193.90. The base case fair value of $240.35 implies 24.0% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.
